Method for treatment of an IL-17A-mediated disease through antibody administration specific to human IL-17A

The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodie...

Full description

Saved in:
Bibliographic Details
Main Authors Morozov, Dmitriy Valentinovich, Ivanov, Roman Alexeevich, Goncharova, Olga Vladimirovna, Sofronova, Ekaterina Vladimirovna, Soloviev, Valeriy Vladimirovich, Korzhavin, Dmitriy Valerievich, Ulitin, Andrey Borisovich, Ustyugov, Yakov Yurevich, Nemankin, Timofey Aleksandrovich, Ekimova, Victoria Mikhailovna, Chernovskaya, Tatyana Veniaminovna, Evdokimov, Stanislav Rudolfovich, Chernykh, Yulia Sergeevna
Format Patent
LanguageEnglish
Published 20.09.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The monoclonal IgG-type antibodies were suggested comprising variable domains represented by a combination of VHH-derivative with a variable domain of the light chain VL. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (Kabat numbering) or combinations thereof. Antibodies of the invention possess increased affinity and improved aggregation stability.
Bibliography:Application Number: US201916564148